Biotech News

Emergent Biosolutions Receives 64 5 Million Contract Modification For Bat Botulism Antitoxin Heptavalent A B C D E F G Equine To Support U S Biodefense Strategy

EBS (EBS)ebs.com2026-04-10 09:30 ESTCompany update

EBS (EBS) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is ebs.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

No closely related headlines were available from the latest feed snapshot.

Emergent BioSolutions

Emergent BioSolutions is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

Stock data

Close
9.12 USD
Market cap
470.56M USD
Exchange
NYSE
Sector
Biotechnology
Location
United States